OTC : IDXG

Interpace Biosciences, Inc.

$1.7 USD

$0.09 (5.59%)

Volume
13.7K
Average Volume
5.5K
Market Capitalization
$47.09M
P/E Ratio
0.32
Dividend Yield
0.00%
Price Target
Year High
$2.40
Year Low
$0.77
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.22
Company Overview

OTC

Thomas W. Burnell

Medical - Diagnostics & Research

Healthcare

IDXG

102

US

USD

https://www.interpace.com

855 776 6419

46062X303

0001054102

Liquidity Metrics

0.02

2.22

2.22

0.54

0.00

Sales & Valuation

$38.73M

1.30

2.03

11.59

0.15

Profitability

$0.89

$24.58M

67.64%

10.77%

142.98%

70.76%

P/E Metrics

0.32

0.00

0.00

Analyst Price Target & Rating

Buy

4/5

7 Analysts

%

Financial Health Scores

-4.59

5/9

$6M

$33.41M

$10.33M

$3.22M

Key Metrics (TTM)

$43.03M

1.19

10.57

2.51

215.31%

11.30%

64.46%

9.83%

$4.86

64 days

Company Executives
Name Title
Sydney D. Finkelstein Chief Pathology Officer
Patrick Kane Vice President & Corporate Controller
Thomas W. Burnell President, Chief Executive Officer & Chairman
Christopher McCarthy Chief Financial Officer & Chief Operating Officer
Nicole Massoll Chief Medical Officer
Poll Results

No votes yet today — be the first to share your view!

About Interpace Biosciences, Inc. (OTC:IDXG) Stock

Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodule ... s for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.

Critical Contrast: Interpace Biosciences (OTCMKTS:IDXG) versus Ethema Health (OTCMKTS:GRST)

2026-08-11 03:59:17

Profitability This table compares Ethema Health and Interpace Biosciences' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Ethema Health -11.61% N/A -7.48% Interpace Biosciences 65.25% 219.07% 105.05% Insider and Institutional Ownership 5.7% of Interpace Biosciences shares are held by institutional investors. 55.7% of Ethema Health shares

Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results

2026-08-10 16:35:00

Q2 Revenue of $9. 1 millionQ2 Income from Continuing Operations of $0. 3 millionQ2 Thyroid volume year-over-year increase of 6%Q2 Thyroid revenue year-over-year increase of 9%Trailing twelve-month thyroid revenue of $36. 1 million, an increase of 11% on a comparable thyroid-only basis PARSIPPANY, NJ, Aug.

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results

2026-05-12 16:06:19

Q1 Revenue of $9. 0 million Q1 Income from Continuing Operations of $0. 8 million Q1 Thyroid volume year-over-year increase of 10% Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update.

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results

2026-05-12 16:06:00

PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update.

Frequently Asked Questions

What is the current Interpace Biosciences, Inc. (IDXG) stock price?

Interpace Biosciences, Inc.(OTC:IDXG) stock price is $1.7 in the last trading session. During the trading session, IDXG stock reached the peak price of $2.4 while $0.77 was the lowest point it dropped to. The percentage change in IDXG stock occurred in the recent session was 5.59% while the dollar amount for the price change in IDXG stock was $0.09.

IDXG's industry and sector of operation?

The OTC listed IDXG is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of IDXG?

Sydney D. Finkelstein | Chief Pathology Officer
Patrick Kane | Vice President & Corporate Controller
Thomas W. Burnell | President, Chief Executive Officer & Chairman
Christopher McCarthy | Chief Financial Officer & Chief Operating Officer
Nicole Massoll | Chief Medical Officer

How many employees does IDXG have?

Number of IDXG employees currently stands at 102. IDXG operates from Waterview Plaza, Parsippany, NJ 07054, US.

Link for IDXG official website?

Official Website of IDXG is: https://www.interpace.com

How do I contact IDXG?

IDXG could be contacted at phone #855 776 6419 and can also be accessed through its website. IDXG operates from Waterview Plaza, Parsippany, NJ 07054, US.

How many shares of IDXG are traded daily?

The average number of IDXG shares traded daily for last 3 months was 5.5K.

What is the market cap of IDXG currently?

The market value of IDXG currently stands at $47.09M with its latest stock price at $1.7